A trailblazing team of scientists from Oxperial BioHealth in Oxford has introduced Green Products Photodynamic Therapy (GPDT), an innovative new approach to cancer treatment. Presented at the 2024 Pharmaceutical Science Conference in Barcelona and the 20th Guangzhou International Symposium on Molecular Medicine, GPDT, branded as “Sunshine Against Cancer,” is gaining international recognition for its potential to transform oncology.
Led by Dr. Daniel T. H. Chen, Dr. Ta-Chun Liu, Pharmacist Shin-Yi Huang, and Dr. Yao-Kuan Chen, the team demonstrated that GPDT, a purely plant-based therapy, triggers apoptosis (programmed cell death) in human cancer cells. This process is notably enhanced by exposure to sunlight. The therapy utilises the natural healing properties of plant chlorophyll and other botanical compounds, offering a sustainable, non-invasive alternative to traditional cancer treatments.
GPDT has already secured patents in the UK and Taiwan, with applications for multinational protection underway. This revolutionary therapy is designed to inhibit tumour cell growth and differentiation. Its unique combination of photodynamic activation and eco-friendly ingredients marks it as a major breakthrough in global cancer research and care.
The global medical and pharmaceutical industries have embraced GPDT as a potential turning point in the fight against cancer. Could the integration of sunlight and natural compounds provide a new pathway for cancer treatment? The evidence suggests that this exciting prospect is within reach.
Cancer continues to rank as the leading cause of death worldwide, yet GPDT offers a fresh perspective on treatment. At the 2024 Barcelona Global Pharmacology Symposium, Dr. Daniel T. H. Chen unveiled findings that position GPDT as a therapy that leverages sunlight and natural plant extracts to target cancer cells.
By capturing the 400nm-700nm spectrum of sunlight, GPDT activates botanical components to produce reactive oxygen species, including single-state oxygen molecules. These molecules have shown cancer cell inhibition in laboratory tests, positioning the therapy as a non-invasive and complementary option for patients seeking alternatives to conventional methods often associated with harsh side effects.
“GPDT is the world’s first natural photodynamic solution, combining sunlight and botanicals to offer a natural option for maintaining cellular balance and supporting overall health. By integrating outdoor sunlight exposure and plant-based dietary elements, individuals can pursue a more natural, holistic path to wellness,” explained Dr. Daniel Chen.
Oxperial BioHealth plans to release PropoLight, the first GPDT-based product, in early 2025. Marketed as a premium health supplement, PropoLight aims to support cellular health and overall wellness, particularly for those seeking natural ways to enhance their health.
According to research partner Shin-Yi Huang, PropoLight will undergo rigorous testing and certifications in the UK and US. These efforts are part of a broader strategy to develop a pharmaceutical-grade version of the product, paving the way for its global launch.
The debut of PropoLight is a key milestone, merging natural health products with lifestyle-focused wellness solutions. Looking to the future, Oxperial BioHealth plans to expand its range of offerings, including advanced pharmaceutical-grade therapies, driving further innovation in holistic healthcare worldwide.
